论文部分内容阅读
目的探讨西洛他唑与瑞舒伐他汀对2型糖尿病合并冠心病患者脂代谢的影响。方法 108例2型糖尿病合并冠心病患者,观察患者治疗前后高敏C反应蛋白(hs-CRP)、血清淀粉样蛋白A(SAA)、血浆骨桥蛋白(OPN)、总胆固醇(TC)、甘油三脂(TG)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)等水平变化。结果患者治疗后TC、TG和LDL-C水平分别为(4.13±1.28)mmol/L、(1.71±0.88)mmol/L和(2.24±0.77)mmol/L均较治疗前有所下降,差异有统计学意义(P<0.05),而治疗后HDL-C水平较治疗前有所提高,差异有统计学意义(P<0.05);患者治疗后SAA、hs-CRP和OPN水平分别为(2.23±0.18)mg/L、(3.11±1.06)mg/L和(68.32±12.05)ng/L显著低于治疗前,差异有统计学意义(P<0.05);未发现有肝肾功能损害等严重不良反应发生。结论西洛他唑与瑞舒伐他汀治疗2型糖尿病合并冠心病,能有效改善患者血脂情况,降低SAA、hs-CRP和OPN水平。
Objective To investigate the effects of cilostazol and rosuvastatin on lipid metabolism in type 2 diabetic patients with coronary heart disease. Methods One hundred and eighty patients with type 2 diabetes mellitus complicated with coronary heart disease were enrolled in this study. The levels of hs-CRP, SAA, OPN, TC, (TG), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C) and other level changes. Results The levels of TC, TG and LDL-C in the patients after treatment were (4.13 ± 1.28) mmol / L and (1.71 ± 0.88) mmol / L and (2.24 ± 0.77) mmol / L respectively, (P <0.05), while the level of HDL-C after treatment was significantly higher than that before treatment (P <0.05). The levels of SAA, hs-CRP and OPN in the patients after treatment were (2.23 ± 0.18) mg / L, (3.11 ± 1.06) mg / L and (68.32 ± 12.05) ng / L were significantly lower than those before treatment (P <0.05); no serious dysfunction such as liver and kidney dysfunction The reaction took place. Conclusion Cilostazol and rosuvastatin can reduce the level of SAA, hs-CRP and OPN in type 2 diabetic patients with coronary heart disease.